On November 15, 2026, the FDA issued Summit Therapeutics a Complete Response Letter, saying it could not approve ivonescimab with platinum-based chemotherapy for advanced or metastatic non-small cell lung cancer after prior EGFR-targeted treatment.
The FDA’s main concern was that the Phase 3 HARMONi trial did not show a statistically significant improvement in overall survival. Although the treatment delayed cancer progression, the agency said that benefit alone did not establish a favorable benefit-risk profile.
The decision applies to this specific, previously treated EGFR-mutated lung cancer group—not to ivonescimab’s entire development program. Summit and Akeso may continue pursuing other indications and further evidence.
Sources:
US FDA Rejects Summit's China-Originated Lung Cancer Drug
FDA rejects Summit's ivonescimab, derailing US arrival of much-hyped PD-1xVEGF class
FDA rejects lung cancer treatment ivonescimab from ...
US FDA declines to approve Summit lung cancer drug after ...
U.S. FDA rejects Summit's China-originated lung cancer drug
US FDA Rejects Summit’s China-Originated Lung Cancer Drug
Summit's PD-1xVEGF rejected by FDA in lung cancer
US FDA rejects closely watched lung cancer drug from China
FDA rejects approval of Summit, Akeso's PD-1/VEGF bispecific in lung cancer
FDA rejects Summit, Akeso's ivonescimab in narrow lung ...
FDA won't approve Summit, Akeso's ivonescimab
U.S. rejects China's breakout cancer drug | Aju Press
FDA Rejects Summit Therapeutics' Lung Cancer Drug Application, S